However, despite the clinical success of anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1), and anti-PD-1 ligand (PD-L1), only a subset of cancer patients experiences a long-term survival benefit. This evidence concerns the gene CD274 and cancer.